Shintaro Kanda
Overview
Explore the profile of Shintaro Kanda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
1043
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shiraishi Y, Nomura S, Sugawara S, Horinouchi H, Yoneshima Y, Hayashi H, et al.
Lancet Respir Med
. 2024 Aug;
12(11):877-887.
PMID: 39159638
Background: The combination of platinum-based chemotherapy and an antibody to PD-1 or to its ligand PD-L1, with or without an antibody to CTLA-4, has improved the survival of individuals with...
2.
Yazaki T, Kimoto M, Minagawa A, Maruno T, Yamanaka M, Sonehara K, et al.
Am J Case Rep
. 2024 Jun;
25:e943466.
PMID: 38822519
BACKGROUND Various resistance mechanisms of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) have been reported, and approximately half of the cases show a T790M point mutation as resistance...
3.
Araki T, Kanda S, Yazaki T, Hirabayashi T, Komatsu M, Sonehara K, et al.
Respir Investig
. 2024 May;
62(4):677-680.
PMID: 38776647
MET exon14 skipping mutations (METex14s) are rarely reported as a potential resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs). The efficacy of targeted therapy against METex14s emerging after osimertinib resistance...
4.
Iwasa Y, Kitoh R, Yokota Y, Hori K, Kasuga M, Kobayashi T, et al.
Cancer Diagn Progn
. 2024 Mar;
4(2):182-188.
PMID: 38434918
Background/aim: Inflammation and nutrition-based biomarkers, such as the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), lymphocyte/monocyte ratio (LMR), C-reactive protein/albumin ratio (CAR), prognostic nutritional index (PNI), systemic immune inflammation index (SII),...
5.
Araki T, Kanda S, Obara M, Agatsuma T, Kakizaki Y, Hama M, et al.
Respir Investig
. 2024 Jan;
62(2):262-268.
PMID: 38245931
Background: Rechallenge therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is known to confer some clinical benefit for patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC)....
6.
Kobayashi T, Nishino Y, Takiguchi T, Kanda S, Otsuki K, Tanaka Y, et al.
BMC Pulm Med
. 2023 Sep;
23(1):322.
PMID: 37658334
Objective: This study was performed to validate the epidemiology, initial treatment, and clinical practice of lung cancer patients in the Hokushin region, Japan. Methods: We retrospectively surveyed data of 5503...
7.
Atagi T, Kanda S, Kawakami H, Kobayashi T, Koizumi T
Intern Med
. 2023 Jul;
63(7):1027-1031.
PMID: 37495537
A 42-year-old man visited our hospital due to a gradually swelling subcutaneous mass on the back of the right shoulder. The biopsy specimen was diagnosed pathologically as pleomorphic liposarcoma. Systemic...
8.
Araki T, Kanda S, Komatsu M, Sonehara K, Tateishi K, Takada M, et al.
Transl Lung Cancer Res
. 2023 Jul;
12(6):1320-1327.
PMID: 37425417
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC) and contributed to the development of precision medicine. Osimertinib...
9.
Ide T, Nishino Y, Takiguchi T, Kanda S, Otsuki K, Hayashi R, et al.
BMC Pulm Med
. 2023 Jun;
23(1):228.
PMID: 37365528
Objective: Appropriate monitoring and management of chemotherapy-induced nausea and vomiting (CINV) with prophylactic antiemetics is important for cancer patients. This study was performed to validate the clinical practice of antiemetic...
10.
Araki T, Kanda S, Horinouchi H, Ohe Y
Jpn J Clin Oncol
. 2023 Jun;
53(7):547-561.
PMID: 37279591
Osimertinib, a third-generation EGFR TKI, is the standard therapy for previously untreated EGFR-mutated non-small cell lung cancer patients following the landmark FLAURA study. However, resistance inevitably hinders patient prognosis, increasing...